Physician profile
Jessica Evelson
NPI 1053504845
$529.36
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $162 · 2022: $15.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $300.68 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $84.24 | 2019-2020 | |
| Shire North American Group INC | $19.89 | 2019 | |
| Lundbeck LLC | $19.80 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.19 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.47 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.58 | 2022 | |
| Tris Pharma INC | $15.16 | 2019 | |
| Neurocrine Biosciences, INC. | $14.46 | 2019 | |
| Allergan, INC. | $12.15 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.74 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Evelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.